Updated results of first-line chemotherapy combined with an immune checkpoint inhibitor for advanced extrapulmonary neuroendocrine carcinoma: A single arm, phase II study

#4392

Introduction: NEC is a rare, aggressive cancer with limited response to standard first-line chemo (etoposide + cisplatin/carboplatin, EP/EC).

Aim(s): This study aims to evaluate the efficacy and safety of combining EP/EC chemo with camrelizumab for advanced extrapulmonary NEC.

Materials and methods: Unresectable/metastatic extrapulmonary NEC pts naive to systemic therapy will receive camrelizumab (200 mg, q3w) + EP/EC chemo. Stable/remitting patients continue camrelizumab up to 24 months. Pts with stable disease or remission after 6 cycles will continue maintenance camrelizumab for up to 24 months. The primary endpoint is 6-month PFS rate. The secondary end points are ORR, DCR, PFS, OS and adverse reactions (AEs). Additionally, next-generation sequencing (NGS) and PD-L1 immunohistochemistry (IHC) will be utilised to investigate potential biomarkers that may predict the efficacy of the treatment.

Conference:

Presenting Author:

Authors: Cao D, Li X, Li R, Wang X, Yang Y,

Keywords: neuroendocrine carcinoma, First-line, chemotherapy, camrelizumab,